Call Us - We're Easy to Talk To (214) 999-9999

Judge Rules Pfizer Won’t Face Class-Action Suits Over Off-Label Marketing of Neurontin

Bloomberg News reported, “Pfizer Inc. the world’s largest drugmaker, won’t face class-action lawsuits by health-insurance companies and patients on claims it improperly marketed the epilepsy drug Neurontin for unapproved uses, a judge ruled.” US District Judge Patti Saris found that “consumer plaintiffs, seeking separate classes for treatment of individual illnesses, failed to support claims connecting off-label marketing to doctors’ actions in prescribing the drug.” She stated that “the plaintiffs would have to demonstrate doctor-by-doctor that defendants’ fraudulent misrepresentations or omissions during the off-label promotion caused the doctor to prescribe the medication.” The company was “accused of promotion the drug for uses not approved by the US Food and Drug Administration, in violation of FDA rules, increasing Neurontin sales.” Consumers were split “into sub-classes, depending on the use prescribed.”

From the American Association for Justice news release.

Bob Kraft

I am a Dallas, Texas lawyer who has had the privilege of helping thousands of clients since 1971 in the areas of Personal Injury law and Social Security Disability.

About This Blog

The title of this blog reflects my attitude toward those government agencies and insurance companies that routinely mistreat injured or disabled people. As a Dallas, Texas lawyer, I've spent more than 45 years trying to help those poor folk, and I have been frustrated daily by the actions of the people on the other side of their claims. (Sorry if I offended you...)

If you find this type of information interesting or helpful, please visit my law firm's main website at You will find many more articles and links. Thank you for your time.

Find us on your preferred network